<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id><journal-title-group><journal-title>BMC Cancer</journal-title></journal-title-group><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25881079</article-id><article-id pub-id-type="pmc">4412099</article-id><article-id pub-id-type="publisher-id">1146</article-id><article-id pub-id-type="doi">10.1186/s12885-015-1146-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>A retrospective analysis of <italic>RET</italic> translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Platt</surname><given-names>Adam</given-names></name><address><email>adam.platt@astrazeneca.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Morten</surname><given-names>John</given-names></name><address><email>john.morten@astrazeneca.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ji</surname><given-names>Qunsheng</given-names></name><address><email>qunsheng.ji@astrazeneca.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Elvin</surname><given-names>Paul</given-names></name><address><email>paul.elvin@astrazeneca.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Womack</surname><given-names>Chris</given-names></name><address><email>chris.womack@astrazeneca.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Su</surname><given-names>Xinying</given-names></name><address><email>xinying.su@astrazeneca.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Donald</surname><given-names>Emma</given-names></name><address><email>emma.donald@astrazeneca.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Gray</surname><given-names>Neil</given-names></name><address><email>adam.platt@astrazeneca.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Read</surname><given-names>Jessica</given-names></name><address><email>jessica.read@astrazeneca.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bigley</surname><given-names>Graham</given-names></name><address><email>graham.bigley@astrazeneca.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Blockley</surname><given-names>Laura</given-names></name><address><email>laura.blockley@astrazeneca.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Cresswell</surname><given-names>Carl</given-names></name><address><email>carl.cresswell@astrazeneca.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Dale</surname><given-names>Angela</given-names></name><address><email>angela.dale@astrazeneca.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Davies</surname><given-names>Amanda</given-names></name><address><email>amanda.davies@astrazeneca.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Tianwei</given-names></name><address><email>tianwei.zhang@astrazeneca.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Fan</surname><given-names>Shuqiong</given-names></name><address><email>shuqiong.fan@astrazeneca.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Fu</surname><given-names>Haihua</given-names></name><address><email>haihua.fu@astrazeneca.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Gladwin</surname><given-names>Amanda</given-names></name><address><email>amanda.gladwin@astrazeneca.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Harrod</surname><given-names>Grace</given-names></name><address><email>grace.harrod@astrazeneca.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Stevens</surname><given-names>James</given-names></name><address><email>james.stevens@astrazeneca.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Williams</surname><given-names>Victoria</given-names></name><address><email>victoria.williams@astrazeneca.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ye</surname><given-names>Qingqing</given-names></name><address><email>qingqing.ye@astrazeneca.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Zheng</surname><given-names>Li</given-names></name><address><email>li.zheng@astrazeneca.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>de Boer</surname><given-names>Richard</given-names></name><address><email>Richard.DeBoer@wh.org.au</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Herbst</surname><given-names>Roy S</given-names></name><address><email>roy.herbst@yale.edu</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Jin-Soo</given-names></name><address><email>jslee@ncc.re.kr</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Vasselli</surname><given-names>James</given-names></name><address><email>vassellija@MedImmune.com</email></address><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><aff id="Aff1"><label>1</label>AstraZeneca, da Vinci Building, Melbourn Science Park, Cambridge Road, Melbourn, Royston, Hertfordshire SG8 6HB UK </aff><aff id="Aff2"><label>2</label>AstraZeneca, Macclesfield, UK </aff><aff id="Aff3"><label>3</label>Innovation Cancer Center, AstraZeneca R&#x00026;D, Shanghai, China </aff><aff id="Aff4"><label>4</label>Department of Hematology &#x00026; Medical Oncology, Western Hospital, Melbourne, Victoria Australia </aff><aff id="Aff5"><label>5</label>Yale Comprehensive Cancer Center, New Haven, CT USA </aff><aff id="Aff6"><label>6</label>National Cancer Center, Goyang, Republic of Korea </aff><aff id="Aff7"><label>7</label>AstraZeneca, Wilmington, DE USA </aff><aff id="Aff8"><label>8</label>Current address &#x02013; MedImmune, Gaithersburg, MD USA </aff></contrib-group><pub-date pub-type="epub"><day>23</day><month>3</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>3</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>15</volume><elocation-id>171</elocation-id><history><date date-type="received"><day>18</day><month>3</month><year>2014</year></date><date date-type="accepted"><day>27</day><month>2</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; Platt et al.; licensee BioMed Central. 2015</copyright-statement><license license-type="open-access"><license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>To determine the prevalence of <italic>RET</italic> rearrangement genes, <italic>RET</italic> copy number gains and expression in tumor samples from four Phase III non-small-cell lung cancer (NSCLC) trials of vandetanib, a selective inhibitor of VEGFR, RET and EGFR signaling, and to determine any association with outcome to vandetanib treatment.</p></sec><sec><title>Methods</title><p>Archival tumor samples from the ZODIAC (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00312377">NCT00312377</ext-link>, vandetanib&#x02009;&#x000b1;&#x02009;docetaxel), ZEAL (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00418886">NCT00418886</ext-link>, vandetanib&#x02009;&#x000b1;&#x02009;pemetrexed), ZEPHYR (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00404924">NCT00404924</ext-link>, vandetanib vs placebo) and ZEST (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00364351">NCT00364351</ext-link>, vandetanib vs erlotinib) studies were evaluated by fluorescence <italic>in situ</italic> hybridization (FISH) and immunohistochemistry (IHC) in 944 and 1102 patients.</p></sec><sec><title>Results</title><p>The prevalence of <italic>RET</italic> rearrangements by FISH was 0.7% (95% CI 0.3&#x02013;1.5%) among patients with a known result. Seven tumor samples were positive for <italic>RET</italic> rearrangements (vandetanib, <italic>n</italic>&#x02009;=&#x02009;3; comparator, <italic>n</italic>&#x02009;=&#x02009;4). 2.8% (<italic>n</italic>&#x02009;=&#x02009;26) of samples had <italic>RET</italic> amplification (innumerable <italic>RET</italic> clusters, or &#x02265;7 copies in &#x0003e; 10% of tumor cells), 8.1% (<italic>n</italic>&#x02009;=&#x02009;76) had low <italic>RET</italic> gene copy number gain (4&#x02013;6 copies in &#x02265;40% of tumor cells) and 8.3% (<italic>n</italic>&#x02009;=&#x02009;92) were RET expression positive (signal intensity ++ or +++ in &#x0003e;10% of tumor cells). Of <italic>RET</italic>-rearrangement-positive patients, none had an objective response in the vandetanib arm and one patient responded in the comparator arm. Radiologic evidence of tumor shrinkage was observed in two patients treated with vandetanib and one treated with comparator drug. The objective response rate was similar in the vandetanib and comparator arms for patients positive for <italic>RET</italic> copy number gains or RET protein expression.</p></sec><sec><title>Conclusions</title><p>We have identified prevalence for three RET biomarkers in a population predominated by non-Asians and smokers. <italic>RET</italic> rearrangement prevalence was lower than previously reported. We found no evidence of a differential benefit for efficacy by IHC and <italic>RET</italic> gene copy number gains. The low prevalence of <italic>RET</italic> rearrangements (0.7%) prevents firm conclusions regarding association of vandetanib treatment with efficacy in the <italic>RET</italic> rearrangement NSCLC subpopulation.</p></sec><sec><title>Trial registration</title><p>Randomized Phase III clinical trials (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00312377">NCT00312377</ext-link>, ZODIAC; <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00418886">NCT00418886</ext-link>, ZEAL; <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00364351">NCT00364351</ext-link>, ZEST; <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00404924">NCT00404924</ext-link>, ZEPHYR).</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s12885-015-1146-8) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd><italic>RET</italic> rearrangement</kwd><kwd>Vandetanib</kwd><kwd>Non-small-cell lung cancer</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>Cancer treatment paradigms are evolving to exploit the sensitivity of tumors to inhibitors that target the products of genes carrying driver mutations [<xref ref-type="bibr" rid="CR1">1</xref>]. A number of genetic aberrations that drive and maintain tumorigenesis have recently been identified in non-small-cell lung cancer (NSCLC). These include fusion genes generated by chromosomal rearrangements between the rearranged during transfection (<italic>RET</italic>) gene and other genes, most commonly kinesin family 5B (<italic>KIF5B</italic>) and coiled coil domain containing-6 (<italic>CCDC6</italic>) [<xref ref-type="bibr" rid="CR2">2</xref>-<xref ref-type="bibr" rid="CR12">12</xref>]. These fusions lead to overexpression of truncated RET proteins containing the RET kinase domain, which can induce transformation and occur in tumors that rarely harbor mutations in other common drivers, ie epidermal growth factor receptor (<italic>EGFR</italic>), <italic>KRAS</italic>, human epidermal growth factor receptor, and anaplastic lymphoma receptor (<italic>ALK</italic>) genes. <italic>RET</italic> rearrangement was first shown to be associated with papillary thyroid carcinoma (PTC), leading to the fusion oncoprotein (<italic>RET/PTC</italic>) and constitutive activation of RET receptor tyrosine kinase in papillary cancer cells [<xref ref-type="bibr" rid="CR13">13</xref>]. In addition, <italic>RET</italic> mutations are present in the germline of nearly all patients with hereditary forms of medullary thyroid cancer (MTC) [<xref ref-type="bibr" rid="CR14">14</xref>-<xref ref-type="bibr" rid="CR16">16</xref>] and approximately 50% of patients with sporadic MTC have somatic <italic>RET</italic> mutations that are associated with a worse outcome [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p>Vandetanib is a once-daily, oral anticancer agent that selectively inhibits vascular endothelial growth factor receptor (VEGFR), RET and EGFR signaling [<xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR19">19</xref>], and is licensed for the treatment of MTC in several geographical regions. Preclinical studies have demonstrated that vandetanib inhibits RET signaling arising from <italic>RET</italic> mutations in a MTC cell line and inhibits growth of human PTC cell lines that carry spontaneous <italic>RET/PTC</italic> rearrangements [<xref ref-type="bibr" rid="CR19">19</xref>]. In addition, vandetanib has been shown to inhibit the proliferation of cells expressing <italic>RET-KIF5B</italic> [<xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR3">3</xref>] and a human lung adenocarcinoma cell line harboring an endogenous <italic>RET-CCDC6</italic> [<xref ref-type="bibr" rid="CR20">20</xref>].</p><p>Four randomized Phase III clinical trials have evaluated the efficacy of vandetanib in NSCLC in combination with docetaxel (NCT00312377; ZODIAC [<xref ref-type="bibr" rid="CR21">21</xref>]), in combination with pemetrexed (NCT00418886; ZEAL [<xref ref-type="bibr" rid="CR22">22</xref>]) or as a monotherapy (NCT00364351; ZEST [<xref ref-type="bibr" rid="CR23">23</xref>] and NCT00404924; ZEPHYR [<xref ref-type="bibr" rid="CR24">24</xref>]). These studies in unselected patient populations demonstrated antitumor activity of vandetanib, but there was no overall survival benefit when added to standard chemotherapy or as monotherapy versus erlotinib [<xref ref-type="bibr" rid="CR21">21</xref>-<xref ref-type="bibr" rid="CR24">24</xref>]. The aim of this study, a retrospective evaluation of tumor samples from the NSCLC Phase III program, was to determine the prevalence of <italic>RET</italic> rearrangements and other potential RET biomarkers within this population and to investigate any association with outcome to vandetanib treatment.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Overview of NSCLC studies</title><sec id="Sec4"><title>Study treatments and assessment of efficacy</title><p>All four studies are registered at <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/">www.clinicaltrials.gov</ext-link> and were Phase III, multicenter, randomized, double-blind studies conducted in 25 (ZODIAC), 21 (ZEAL), 22 (ZEPHYR) and 22 (ZEST) countries, respectively. Enrollment was conducted between 2006 and 2008. Full details of the study design and methodology have been reported previously [<xref ref-type="bibr" rid="CR21">21</xref>-<xref ref-type="bibr" rid="CR24">24</xref>]. Briefly, in ZODIAC (NCT00312377), patients received docetaxel in combination with oral vandetanib 100&#x000a0;mg/day (<italic>n</italic>&#x02009;=&#x02009;694) or matched placebo (<italic>n</italic>&#x02009;=&#x02009;697). Docetaxel 75&#x000a0;mg/m<sup>2</sup> was administered as an intravenous infusion every 21&#x000a0;days, for a maximum of six cycles. In ZEAL (NCT00418886), patients received pemetrexed in combination with oral vandetanib, 100&#x000a0;mg/day (<italic>n</italic>&#x02009;=&#x02009;256) or matched placebo (<italic>n</italic>&#x02009;=&#x02009;278). Pemetrexed 500&#x000a0;mg/m<sup>2</sup> was administered as an intravenous infusion every 21&#x000a0;days, for a maximum of six cycles. Vandetanib was evaluated as a monotherapy in two of the studies: in ZEPHYR (NCT00404924), patients received vandetanib 300&#x000a0;mg/day (<italic>n</italic>&#x02009;=&#x02009;617) or placebo (<italic>n</italic>&#x02009;=&#x02009;307); and in ZEST (NCT00364351), patients received vandetanib 300&#x000a0;mg/day (<italic>n</italic>&#x02009;=&#x02009;623) or erlotinib 150&#x000a0;mg/day (<italic>n</italic>&#x02009;=&#x02009;617). Objective tumor assessments were categorized using Response Evaluation Criteria in Solid Tumors (RECIST; version 1.0).</p></sec><sec id="Sec5"><title>Patient eligibility</title><p>Data were evaluated from adult patients with histologically or cytologically confirmed locally advanced or metastatic (stage IIIB to IV) NSCLC after failure of: first-line anticancer therapy (ZODIAC and ZEAL); one or two chemotherapy regimens (ZEST); or an EGFR inhibitor following one or two chemotherapy regimens (ZEPHYR). For all studies, inclusion criteria included: World Health Organization performance status 0&#x02013;2; life expectancy &#x02265;12&#x000a0;weeks and no significant hematologic, hepatic, renal or cardiac abnormalities. Patients with squamous cell histology were also eligible. Prior treatment with VEGFR inhibitors (all studies), docetaxel (ZODIAC only), pemetrexed (ZEAL only) and EGFR inhibitors (ZEST only) was not permitted. Prior treatment with bevacizumab (all studies) and cetuximab (ZEST only) was allowed.</p></sec><sec id="Sec6"><title>Ethics statements</title><p>All patients provided written informed consent, the trials were approved by all relevant institutional ethical committees or review bodies (The University of Texas MD Anderson Cancer Center Surveillance Committee, Houston, TX, USA; The Royal Melbourne Research Foundation, Melbourne, Australia; Institutional Review Board of National Cancer Center, Gyeonggi-do, Republic of Korea; Cedars-Sinai Medical Center Institutional Review Board, Beverly Hills, CA, USA) and was conducted in accordance with the Declaration of Helsinki, Good Clinical Practice, and the AstraZeneca policy on Bioethics [<xref ref-type="bibr" rid="CR25">25</xref>]. Data were generated in accordance with the Medical and Healthcare Products Regulatory Agency Good Clinical Practice Guidelines for laboratories [<xref ref-type="bibr" rid="CR26">26</xref>].</p></sec><sec id="Sec7"><title>Samples</title><p>Archival tumor specimens were sampled prior to enrollment of patients onto study. Provision of these samples for genetic/immunohistochemical (IHC) assessment was not compulsory in any study, resulting in collection from approximately one third of patients. There was no observable bias to sampling consent. Tumor samples were supplied as formalin-fixed paraffin-embedded biopsies, resections or sections and could be obtained at any time during the respective study. Cell lines used as controls in IHC were supplied as cell pellets and stored at &#x02212;80&#x000b0;C prior to use. All analyses were carried out in AstraZeneca laboratories in the UK and China.</p></sec></sec><sec id="Sec8"><title>Assay methods</title><sec id="Sec9"><title>Fluorescence in situ hybridization (FISH) analysis</title><p><italic>RET-KIF5B</italic>, alternative <italic>RET</italic> rearrangements and <italic>RET</italic> gene amplifications were identified using a FISH probe set of four fluorescent-labeled bacterial artificial chromosome (BAC) clone-derived DNA probes designed in-house: RP11-124O11 (located upstream of <italic>RET</italic>) labeled with spectrum red; RP11-718J13 (located immediately downstream of <italic>RET</italic>) labeled with spectrum green (fluorescein isothiocyanate); RP11-983E11 (located upstream of <italic>KIF5B</italic> exon 2) labeled with spectrum gold (5[<xref ref-type="bibr" rid="CR6">6</xref>]-carboxyrhodamine 6G deoxyuridine-5&#x02032;-triphosphate [dUTP]); and centromere of chromosome 10 labeled with spectrum aqua (diethylaminocoumarin-5-dUTP; Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). For tissue samples assessed at the UK site, these probes were sourced from Empire Genomics LLC, Buffalo, NY; for tissue samples assessed at the China site, the probes were generated in-house. BACs and labels used at both sites were identical. Sections were processed with reagents from the Histology FISH accessory kit (Dako, Dako Corporation, Carpinteria, CA, USA, cat #K5799) according to the manufacturer&#x02019;s instructions. Briefly at the UK site, formalin-fixed, paraffin-embedded sections (4&#x000a0;&#x003bc;m) were mounted on glass slides. Sections were deparaffinized in xylene, hydrated through a graded ethanol series, and then incubated with the accessory kit pretreatment solution at 95&#x02013;100&#x000b0;C for 10&#x000a0;minutes. The sections were then washed and pepsin digestion was carried out at 37&#x000b0;C in a Dako hybridizer for 5&#x000a0;minutes; the sections were dehydrated through ethanol and allowed to air dry. The fluorescent probe mix was applied and then the probe and section co-denatured in a Dako hybridizer at 83&#x000b0;C for 3&#x000a0;minutes followed by overnight incubation at 37&#x000b0;C. The sections were washed in 1x saline-sodium citrate (SSC)/0.3% Igepal at 72&#x000b0;C for 2&#x000a0;minutes, followed by 2x SSC at room temperature, before dehydration through ethanol. Sections were mounted in Dako antifade mounting media (Dako, #K5799). The procedure at the China site was similar, except that the sections were incubated with the Spotlight tissue pretreatment kit (Invitrogen, Carlsbad, CA, USA, cat #00-8401) and processed as previously described [<xref ref-type="bibr" rid="CR27">27</xref>].<fig id="Fig1"><label>Figure 1</label><caption><p><bold>Representative FISH images. (A)</bold> Unknown <italic>RET</italic> rearrangement, <bold>(B)</bold><italic>RET-KIF5B</italic> fusion, <bold>(C)</bold><italic>RET</italic> gene amplifications and <bold>(D)</bold> low <italic>RET</italic> gene copy number gain. <bold>(E)</bold> Loci for RET FISH probes.</p></caption><graphic xlink:href="12885_2015_1146_Fig1_HTML" id="d30e893"/></fig></p><p>The FISH gene fusion assay had previously been validated in a pilot study, which confirmed a FISH assay defined <italic>RET-KIF5B</italic> positive NSCLC tumor by sequencing (Additional file <xref rid="MOESM1" ref-type="media">1</xref>). Assessment of FISH signal was carried out by investigators blinded to clinical response. Preliminary assessment was performed at 60x magnification to identify any alterations in the distribution of the red and green signals. When these were observed, 50 tumor cells were analyzed at 100x magnification for the number of red, green, paired red/green, gold, paired green/gold and blue signals in 10&#x02013;15 tumor cells from up to four regions of the tumor section. A further region was then analyzed by a second blinded observer. To describe tumor heterogeneity, estimation of the proportion and distribution of cells with <italic>RET</italic> events was determined independently by two observers.</p></sec><sec id="Sec10"><title>Immunohistochemistry</title><p>Sections were deparaffinized and rehydrated as described above. Antigen retrieval was performed at 110&#x000b0;C for 5&#x000a0;minutes in Target Retrieval Solution (pH&#x000a0;9.0; Dako, #S2367) in a RHS-2 microwave processor (Milestone, Sorisole, Italy) within a pressurized reaction vessel. Endogenous peroxidase activity was quenched by incubating the sections in 3% hydrogen peroxide for 20&#x000a0;minutes at room temperature and non-specific binding was blocked by incubating in serum-free protein block (Dako, #X0909) for 20&#x000a0;minutes at room temperature. Sections were labeled with a rabbit anti-RET monoclonal antibody (1:1000 dilution, clone EPR2871, Epitomics, Burlingame, CA, USA; see Additional file <xref rid="MOESM1" ref-type="media">1</xref> for antibody specificity and immunohistochemistry validation; Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1) and RET expression was visualized with EnVision&#x02122; FLEX+ (Dako, #K8012). Sections were counterstained with hematoxylin. Cell lines (TT, MiaPaCa, SKNMC and Panc1) and tissue samples (human non-inflamed appendix and in-house NSCLC tissue microarray) were used as controls for RET immunostaining.</p></sec></sec><sec id="Sec11"><title>Statistical analysis</title><p>For FISH analysis, tumors were categorized as positive for <italic>RET</italic> rearrangement if &#x0003e;10% of the tumor cells presented with broken-apart red and green <italic>RET</italic> signals; this could be further classified as positive for <italic>RET-KIF5B</italic> if the broken-apart red/green signal was accompanied by a paired green/gold signal. Tumors were categorized as low <italic>RET</italic> gene copy number gain if &#x02265;40% of tumor cells had 4&#x02013;6 copies of red/green <italic>RET</italic> signals. Tumors were categorized as amplified if &#x0003e;10% of tumor cells had &#x02265;7 red/green signals or signal clusters. In the IHC analysis, tumor samples with &#x0003e;100 intact tumor cells were assessed by a system similar to that described previously [<xref ref-type="bibr" rid="CR8">8</xref>]. Tumors were categorized as RET expression positive where the staining signal intensity was ++ or +++ (0 to +++ scale) in &#x0003e;10% of tumor cells. The objective response rate (ORR) was presented by RET biomarker status and treatment arm with corresponding 95% confidence intervals (CIs). Prevalence rates were estimated across all patients with a known result (including those not randomized to treatment) and were presented as a percentage with corresponding 95% CIs.</p></sec></sec><sec id="Sec12" sec-type="results"><title>Results</title><sec id="Sec13"><title>Patients</title><p>From 4089 patients across the four NSCLC studies, 1291 and 1234 screened patients had tumor samples available for FISH and IHC analysis, respectively. Evaluable data were obtained for 944 (FISH; Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2) and 1102 (IHC; Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S3) patients, with seven and eight patients donating FISH and IHC samples, respectively, not randomized to treatment. Failure rates in the IHC analysis (10.7%) were largely due to an inadequate number of tumor cells in the samples, whereas in the FISH analysis, failure rates (26.9%) were largely due to an inadequate number of tumor cells or sample quality. The median age of patients was 61&#x000a0;years; approximately two-thirds were white, with the remainder predominantly of Asian origin. Most patients (61%) presented with adenocarcinoma. Patient demographics and baseline characteristics for patients with tumor samples evaluable for FISH or IHC analysis and clinicopathologic characteristics of patients and their RET biomarker status are outlined in Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Tables S2&#x02013;S4, respectively.</p></sec><sec id="Sec14"><title>Prevalence of RET biomarkers</title><p>In this NSCLC patient population, the overall prevalence of <italic>RET</italic> rearrangements was 0.7% (95% CI 0.3&#x02013;1.5) among patients with a known result. Seven tumor samples were classified as positive for <italic>RET</italic> rearrangements (vandetanib treatment, <italic>n</italic>&#x02009;=&#x02009;3; comparator treatment, <italic>n</italic>&#x02009;=&#x02009;4; Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>; Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a and b). Five of the seven <italic>RET</italic> rearrangements were <italic>RET-KIF5B</italic> and the other two had unknown fusion partners with <italic>RET</italic>. Single red or green signals without a corresponding 3&#x02032; or 5&#x02032; <italic>RET</italic> signal were occasionally seen in samples but were not scored as rearrangements.<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Frequency of RET biomarkers in vandetanib Phase III NSCLC trial program</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3">Clinical study</th><th colspan="8">RET biomarker, n (%) [95% CI]</th></tr><tr><th colspan="2"><italic>RET</italic>rearrangement</th><th colspan="2"><italic>RET</italic>amplification</th><th colspan="2">Low<italic>RET</italic>gene copy number gain</th><th colspan="2">RET expression</th></tr><tr><th>Van</th><th>Comp</th><th>Van</th><th>Comp</th><th>Van</th><th>Comp</th><th>Van</th><th>Comp</th></tr></thead><tbody><tr><td>ZODIAC + ZEAL</td><td>1</td><td>2**</td><td>6</td><td>7</td><td>14</td><td>14</td><td>16</td><td>24</td></tr><tr><td>ZEPHYR</td><td>2</td><td>1</td><td>2</td><td>3</td><td>19</td><td>5</td><td>18</td><td>10</td></tr><tr><td>ZEST</td><td>0</td><td>1**</td><td>4</td><td>2</td><td>8</td><td>14</td><td>12</td><td>10</td></tr><tr><td>Untreated*</td><td colspan="2">&#x02013;</td><td colspan="2">2</td><td colspan="2">2</td><td colspan="2">2</td></tr><tr><td rowspan="2">Non-Asian</td><td colspan="2">5/632 (0.8)</td><td colspan="2">19/632 (3.0)</td><td colspan="2">49/632 (7.7)</td><td colspan="2">52/756 (6.9)</td></tr><tr><td colspan="2">[0.3&#x02013;1.8]</td><td colspan="2">[1.8&#x02013;4.6]</td><td colspan="2">[5.7&#x02013;10.0]</td><td colspan="2">[5.2&#x02013;8.9]</td></tr><tr><td rowspan="2">Asian</td><td colspan="2">2/305 (0.7)</td><td colspan="2">7/305 (2.3)</td><td colspan="2">27/305 (8.8)</td><td colspan="2">40/346 (11.6)</td></tr><tr><td colspan="2">[0.1&#x02013;2.3]</td><td colspan="2">[0.9&#x02013;4.6]</td><td colspan="2">[5.9&#x02013;12.5]</td><td colspan="2">[8.4&#x02013;15.4]</td></tr><tr><td rowspan="2">
<bold>Overall</bold>
</td><td colspan="2">
<bold>7/937 (0.7)</bold>
</td><td colspan="2">
<bold>26/937 (2.8)</bold>
</td><td colspan="2">
<bold>76/937 (8.1)</bold>
</td><td colspan="2">
<bold>92/1102 (8.3)</bold>
</td></tr><tr><td colspan="2">
<bold>[0.3&#x02013;1.5]</bold>
</td><td colspan="2">
<bold>[1.8&#x02013;4.0]</bold>
</td><td colspan="2">
<bold>[6.4&#x02013;10.0]</bold>
</td><td colspan="2">
<bold>[6.8&#x02013;10.1]</bold>
</td></tr></tbody></table><table-wrap-foot><p>Comp, comparator; Van, vandetanib. *One patient randomized to ZODIAC and one randomized to ZEAL did not receive treatment. **One RET rearrangement with an unknown, non-<italic>KIF5B</italic> fusion partner was identified in the ZEAL comparator and one was identified in the ZEST comparator arm.</p></table-wrap-foot></table-wrap></p><p><italic>RET</italic> gene amplifications and low <italic>RET</italic> gene copy number gains were reported in 26 (2.8%; 95% CI 1.8&#x02013;4.0) and 76 (8.1%; 95% CI 6.4&#x02013;10.0) patients, respectively (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>; Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>c and d). RET expression was positive in samples from 92 (8.3%; 95% CI 6.8&#x02013;10.1) patients (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Tumor cell immunostaining was generally cytoplasmic and diffuse (Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). The prevalence of <italic>RET</italic> rearrangement, RET protein expression, <italic>RET</italic> amplification or low <italic>RET</italic> gene copy number gain was similar for Asian and non-Asian populations (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).<fig id="Fig2"><label>Figure 2</label><caption><p><bold>Representative IHC images positive for RET expression. (A)</bold> Tumor biopsies and <bold>(B)</bold> resections. <bold>(C)</bold> Negative (weak) staining.</p></caption><graphic xlink:href="12885_2015_1146_Fig2_HTML" id="d30e1335"/></fig></p><p>In our study, four out of seven tumors that were positive for <italic>RET</italic> rearrangement expressed RET when evaluated with IHC. Of the remaining three samples, one <italic>RET</italic>-<italic>KIF5B</italic> and two <italic>RET</italic>-other rearrangements did not express any detectable RET protein when evaluated with IHC (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S5). In all IHC-positive cases, RET was predominantly cytoplasmic and typically of moderate to weak intensity. In two cases, RET was only detected in the focal areas of tumor cells. Weak staining for RET was also observed in the stroma of three <italic>RET</italic>-rearrangement-positive tumors. Of the seven <italic>RET</italic>-rearrangement-positive tumors, only one showed amplification which was also positive when evaluated with IHC; this case also showed weak RET staining across all of the stroma present in the sample.</p></sec><sec id="Sec15"><title>Clinical outcome by positive RET biomarker status</title><p>None of the three vandetanib-treated <italic>RET</italic>-rearrangement-positive patients had an objective response (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Radiologic evidence of tumor shrinkage was observed in two of these patients (ZEPHYR, 23% and 33% shrinkage of target lesions). However, a response could not be confirmed at the next visit. One patient in ZODIAC who received docetaxel alone had a confirmed objective response and 32% shrinkage of target lesions at day 85 (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). The ORRs were similar for the vandetanib and comparator arms for patients positive for <italic>RET</italic> amplification (8.3% vs 8.3%), those with low <italic>RET</italic> gene copy number gain (9.8% vs 9.1%) or those positive for RET protein expression (15.2% vs 13.6%, Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). In conclusion, we considered there were too few <italic>RET</italic>-rearrangement-positive patients to draw definitive conclusions regarding efficacy in this patient population. However, the lack of additional benefit observed in the higher prevalence biomarker-positive groups of <italic>RET</italic> amplification and low <italic>RET</italic> gene copy number gain is consistent with these biomarkers having little predictive utility to identify those patients who will benefit from vandetanib therapy.<table-wrap id="Tab2"><label>Table 2</label><caption><p>
<bold>ORRs (RECIST) in patients positive for RET biomarkers</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3">Clinical study</th><th colspan="8">Objective responses, n/N (%)</th></tr><tr><th colspan="2"><italic>RET</italic>rearrangement</th><th colspan="2"><italic>RET</italic>amplification</th><th colspan="2">Low<italic>RET</italic>gene copy number gain</th><th colspan="2">RET expression</th></tr><tr><th>Van</th><th>Comp</th><th>Van</th><th>Comp</th><th>Van</th><th>Comp</th><th>Van</th><th>Comp</th></tr></thead><tbody><tr><td>ZODIAC + ZEAL</td><td>0/1</td><td>1/2</td><td>1/6</td><td>1/7</td><td>2/14</td><td>2/14</td><td>5/16</td><td>3/24</td></tr><tr><td>ZEPHYR</td><td>0/2</td><td>0/1</td><td>0/2</td><td>0/3</td><td>0/19</td><td>0/5</td><td>0/18</td><td>0/10</td></tr><tr><td>ZEST</td><td>0/0</td><td>0/1</td><td>0/4</td><td>0/2</td><td>2/8</td><td>1/14</td><td>2/12</td><td>3/10</td></tr><tr><td>
<bold>Overall</bold>
</td><td>
<bold>0/3 (0.0)</bold>
</td><td>
<bold>1/4 (25.0)</bold>
</td><td>
<bold>1/12 (8.3)</bold>
</td><td>
<bold>1/12 (8.3)</bold>
</td><td>
<bold>4/41 (9.8)</bold>
</td><td>
<bold>3/33 (9.1)</bold>
</td><td>
<bold>7/46 (15.2)</bold>
</td><td>
<bold>6/44 (13.6)</bold>
</td></tr></tbody></table></table-wrap><table-wrap id="Tab3"><label>Table 3</label><caption><p>
<bold>Clinicopathologic characteristics of seven patients positive for</bold>
<bold><italic>RET</italic></bold>
<bold>rearrangements</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Study</th><th>Age (years)</th><th>Sex</th><th>Race</th><th>Smoking status*</th><th>Histology</th><th><italic>EGFR</italic>status</th><th><italic>KRAS</italic>status</th><th>Dose/day</th><th>Exposure</th><th>RECIST response</th><th>Tumor shrinkage</th><th>Reason for discontinuation</th><th>RET partner</th><th>% cells with rearrangements detected</th></tr></thead><tbody><tr><td colspan="15">
<bold>Vandetanib</bold>
</td></tr><tr><td>ZODIAC</td><td>68</td><td>F</td><td>Asian</td><td>Non-smoker</td><td>Adenocarcinoma</td><td>Mutation negative</td><td>Negative</td><td>100 mg</td><td>21 days</td><td>Progressive disease</td><td>&#x02013;</td><td>Progressive disease</td><td>KIF5B</td><td>50%</td></tr><tr><td>ZEPHYR</td><td>69</td><td>F</td><td>White</td><td>Non-smoker</td><td>Adenocarcinoma</td><td>Mutation negative; amplification positive</td><td>Negative</td><td>300 mg</td><td>180 days</td><td>Stable disease</td><td>23% shrinkage of target lesions</td><td>Adverse event</td><td>KIF5B</td><td>75&#x02013;100%</td></tr><tr><td>ZEPHYR</td><td>59</td><td>F</td><td>Asian</td><td>Non-smoker</td><td>Adenocarcinoma</td><td>Mutation negative; amplification positive</td><td>Negative</td><td>300 mg</td><td>57 days</td><td>Progressive disease</td><td>33% shrinkage of target lesions (progressive disease in non-target lesions)</td><td>Progressive disease</td><td>KIF5B</td><td>50&#x02013;75%</td></tr><tr><td colspan="15">
<bold>Comparator</bold>
</td></tr><tr><td>ZODIAC</td><td>59</td><td>F</td><td>White</td><td>Ex-smoker</td><td>Adenocarcinoma</td><td>Mutation negative</td><td>Unknown</td><td>&#x02013;</td><td>Six cycles docetaxel</td><td>Partial response (day 85); progressive disease (day 210)</td><td>32% shrinkage of target lesions at day 85</td><td>Completed six cycles</td><td>KIF5B</td><td>75&#x02013;100%</td></tr><tr><td>ZEAL**</td><td>58</td><td>M</td><td>White</td><td>Ex-smoker</td><td>Large cell carcinoma</td><td>Mutation negative</td><td>Negative</td><td>&#x02013;</td><td>Five cycles pemetrexed</td><td>Progressive disease (day 245)</td><td>None</td><td>Completed five cycles</td><td>Not known</td><td>75&#x02013;100%</td></tr><tr><td>ZEPHYR</td><td>57</td><td>M</td><td>White</td><td>Ex-smoker</td><td>Adenocarcinoma</td><td>Mutation negative</td><td>Negative</td><td>&#x02013;</td><td>26 days placebo</td><td>Progressive disease (day 25)</td><td>None</td><td>Progressive disease</td><td>KIF5B</td><td>75&#x02013;100%</td></tr><tr><td>ZEST**</td><td>70</td><td>M</td><td>White</td><td>Ex-smoker</td><td>Adenocarcinoma</td><td>Mutation negative; amplification positive</td><td>Negative</td><td>&#x02013;</td><td>315 days erlotinib</td><td>Progressive disease (day 166)</td><td>None</td><td>Progressive disease</td><td>Not known</td><td>25&#x02013;50%</td></tr></tbody></table><table-wrap-foot><p>F, female; M, male. *Non-smoker = never smoked &#x0003e;20 g tobacco in lifetime; ex-smoker = stopped smoking &#x02265;1 year ago; occasional smoker = &#x0003c;1 tobacco product per day; habitual smoker = &#x02265;1 tobacco product per day. **<italic>RET</italic> rearrangements with unknown, non-<italic>KIF5B</italic> fusion partners.</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec16" sec-type="discussion"><title>Discussion</title><p>In this retrospective study, the overall prevalence of <italic>RET</italic> rearrangements within the Phase III vandetanib NSCLC clinical program was determined as 0.7% among patients with a known <italic>RET</italic> rearrangement status. We found consistent frequencies of <italic>RET</italic> rearrangement in Asian (0.7%) and non-Asian patients (0.8%). In general, <italic>RET</italic> rearrangement prevalence rates may be considered as low and may vary according to the proportions of smokers, racial origin and histological subtype in the study population. Prevalence rates of <italic>RET</italic> rearrangement in Asian populations have been reported at 1&#x02013;2% for NSCLC [<xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR11">11</xref>] and lung adenocarcinoma [<xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR12">12</xref>], and were estimated as high as approximately 6% in lung adenocarcinoma [<xref ref-type="bibr" rid="CR4">4</xref>]. Our own study contains a high proportion of non-Asian patients (67%, Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2) and smokers/ex-smokers (77%, Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2), in contrast to previous reports on <italic>RET</italic> rearrangement prevalence rates [<xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR12">12</xref>], in which study populations were either entirely or largely Asian and non-smokers.</p><p><italic>RET</italic> rearrangements have previously been reported in squamous cell carcinoma [<xref ref-type="bibr" rid="CR5">5</xref>], lung neuroendocrine tumor [<xref ref-type="bibr" rid="CR5">5</xref>] and adenosquamous tumor [<xref ref-type="bibr" rid="CR11">11</xref>]; however, the majority occur in adenocarcinomas. This is consistent with our findings, which show a higher prevalence of <italic>RET</italic> rearrangements in patients with adenocarcinoma (1.2%, 6/510) compared with those in other histology types (0.2%, 1/427). Our data are not in agreement with a number of studies that report a higher frequency of <italic>RET</italic> rearrangements in non-smokers compared with smokers/ex-smokers; in our study, we have observed three and four <italic>RET</italic> rearrangements, respectively (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>) [<xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR11">11</xref>]. As in previous studies, we did not observe co-occurrence of <italic>RET</italic> rearrangements with <italic>EGFR</italic> and <italic>KRAS</italic> mutations. Interestingly, one of the three <italic>RET-KIF5B</italic> tumors reported by Go <italic>et al.</italic> [<xref ref-type="bibr" rid="CR28">28</xref>] in lung adenocarcinomas negative for <italic>KRAS</italic> and <italic>EGFR</italic> mutations and <italic>ALK</italic> rearrangements was from a smoker. However, all of these observations should be interpreted with caution given the small numbers.</p><p>The techniques used to identify <italic>RET</italic> rearrangement genes in previously reported studies were sequencing [<xref ref-type="bibr" rid="CR2">2</xref>-<xref ref-type="bibr" rid="CR4">4</xref>] or reverse transcription-polymerase chain reaction followed by verification with FISH [<xref ref-type="bibr" rid="CR11">11</xref>], sequencing [<xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR12">12</xref>] or differential expression of 3&#x02032; and 5&#x02032; <italic>RET</italic> exons [<xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR11">11</xref>]. Some of these techniques may underestimate the frequency of <italic>RET</italic> rearrangement genes by failing to detect fusions to partner genes other than <italic>KIF5B</italic>. We used a four-probe FISH assay to detect <italic>RET</italic> rearrangements. This technique is highly sensitive in detecting chromosomal rearrangements and has the advantage of detecting other partners or isoforms, though it is not known whether all these rearrangements are functional. For example, in a study using a split FISH assay to evaluate 1528 lung cancers, 22 tumors were detected with split <italic>RET</italic> signals, of which 12 were confirmed as fusions with <italic>KIF5B</italic> and one with <italic>CCDC6</italic> [<xref ref-type="bibr" rid="CR10">10</xref>] and the remaining nine tumors showed little or no expression of the RET kinase domain.</p><p>Although the prevalence of <italic>RET</italic> rearrangements in NSCLC patients is low, RET inhibition may be efficacious within a subset of patients who carry these genetic aberrations. In this study, there were too few vandetanib-treated patients with <italic>RET</italic> rearrangements to form conclusions regarding association with efficacy. A number of studies have reported increased expression of RET protein in NSCLC tumor cells, not necessarily associated with <italic>RET</italic> rearrangements [<xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR11">11</xref>]. This led us to investigate both IHC and <italic>RET</italic> copy number gain as possible predictive biomarkers for vandetanib response. No difference was observed in the ORRs between vandetanib and comparator arms for IHC and copy number analyses.</p><p>In our study, we observed <italic>RET-KIF5B</italic> and other <italic>RET</italic> rearrangements in samples that were negative for RET protein expression. This observation is in line with previous studies of NSCLC samples which have used a range of anti-RET antibodies (including the Epitomics EPR2871 antibody we have used here) and differing IHC techniques [<xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR28">28</xref>]. Sasaki <italic>et al.</italic> [<xref ref-type="bibr" rid="CR8">8</xref>] reported three cases of RET translocation (from 371 NSCLC samples), all of which had weak positive cytoplasmic staining when evaluated with a 3F8 anti-RET mouse monoclonal antibody (Vector Laboratories, Peterborough, UK). In contrast, when using the EPR2871 antibody used in our study, weak, moderate and strong staining were reported for the three RET translocation positive samples; this suggests that apparent RET expression is dependent on both the antibody and the local IHC protocol used. Another study has reported weak to strong RET expression with IHC when using the 3F8 anti-RET antibody; however, only one of the RET IHC positive cases was also <italic>RET-KIF5B</italic> positive [<xref ref-type="bibr" rid="CR3">3</xref>]. Using the EPR2871 antibody, Kohno <italic>et al.</italic> reported 48/222 NSCLC cases to express RET in the absence of a <italic>RET</italic> fusion; all cases of <italic>RET-KIF5B</italic> were also RET positive with IHC [<xref ref-type="bibr" rid="CR2">2</xref>]. Go <italic>et al.</italic> [<xref ref-type="bibr" rid="CR28">28</xref>] used three different anti-RET antibodies to screen 53 NSCLC cases for RET protein expression. RET IHC positive cases were defined as those with &#x0003e;30% of cells expressing cytoplasmic RET. Three samples that were <italic>RET</italic>-fusion positive with whole transcript sequencing were negative for RET with IHC, whereas RET protein was identified in four samples, none of which harbored a <italic>RET-KIF5B</italic> rearrangement. Taken together, these NSCLC studies, along with our results, suggest that not all cases of <italic>RET-KIF5B</italic> or other <italic>RET</italic> rearrangements express RET protein when evaluated with IHC. RET protein appears to be largely cytoplasmic; however, considerable inter-patient variation and heterogeneity among tumor cells within individual tumors is observed.</p><p>Investigation of RET inhibitors in NSCLC patients with a documented confirmation of a <italic>RET</italic> rearrangement is an active area of research with three clinical studies currently ongoing (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01639508">NCT01639508</ext-link>, <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01823068">NCT01823068</ext-link> and <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01813734">NCT01813734</ext-link>). Results from a study on the use of vandetanib in <italic>RET</italic>-rearrangement-positive NSCLC patients (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01823068">NCT01823068</ext-link>) should provide further insight into the role of vandetanib in this patient population. Preliminary data from <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01639508">NCT01639508</ext-link>, a prospective Phase II trial investigating the use of cabozantinib, a small-molecule inhibitor of MET, VEGFR2 and RET, has been published [<xref ref-type="bibr" rid="CR6">6</xref>]. For the first three patients treated with cabozantinib, two patients showed confirmed partial clinical responses and the third patient had prolonged stable disease approaching 8&#x000a0;months [<xref ref-type="bibr" rid="CR6">6</xref>]. A case study in a patient with poorly differentiated lung adenocarcinoma, positive for a <italic>RET-KIF5B</italic> and refractory for previous chemotherapy, is also noteworthy. In this patient, 4&#x000a0;weeks of treatment with vandetanib 300&#x000a0;mg once daily produced a fluorodeoxyglucose-positron emission tomography/computed tomography response [<xref ref-type="bibr" rid="CR29">29</xref>]. In addition, in a preliminary study in which two heavily pretreated patients with confirmed <italic>RET</italic> rearrangements were treated with vandetanib, stable disease was observed following treatment [<xref ref-type="bibr" rid="CR30">30</xref>].</p></sec><sec id="Sec17" sec-type="conclusion"><title>Conclusions</title><p>This study has demonstrated an overall prevalence of 0.7% for <italic>RET</italic> rearrangements in a large Phase III NSCLC patient population among patients with a known determination of <italic>RET</italic> rearrangement status composed predominantly of non-Asian patients and smokers. <italic>RET</italic> rearrangements were found most frequently, but not exclusively, in adenocarcinomas and occurred in tumors negative for other driver mutations, in agreement with previous reports in predominantly Asian populations. The prevalence of <italic>RET</italic> rearrangement is too low in this unselected population to determine whether <italic>RET</italic>-rearrangement-positive patients can be effectively treated with RET inhibitors, such as vandetanib. Changes in <italic>RET</italic> gene copy number and level of RET protein expression are more frequent aberrations than <italic>RET</italic> rearrangement in this NSCLC population, but also do not provide predictive markers for response to vandetanib. Results from additional studies, specifically in <italic>RET</italic>-rearrangement-positive NSCLC patients, are needed to determine whether this patient population can be effectively treated with RET inhibitors, such as vandetanib. If these studies support <italic>RET</italic> rearrangements as a clinically relevant target, then screening of NSCLC patients for <italic>RET</italic> rearrangements may become part of standard care.</p></sec></body><back><app-group><app id="App1"><sec id="Sec18"><title>Additional file</title><p>
<media position="anchor" xlink:href="12885_2015_1146_MOESM1_ESM.docx" id="MOESM1"><label>Additional file 1:</label><caption><p>
<bold>Supporting information for FISH assay validation, Western blotting/IHC antibody specificity, localization of RET in tumor tissue sections, patient demographics and baseline characteristics for patients with tumor samples evaluable for FISH and/or IHC analysis.</bold>
</p></caption></media>
</p></sec></app></app-group><fn-group><fn><p>Please see related article: http://dx.doi.org/10.1186/s12885-015-1147-7</p></fn><fn><p>Neil Gray deceased.</p></fn><fn><p><bold>Competing interests</bold></p><p>G Bigley, A Dale, S Fan, H Fu, Q Ji, A Platt, J Read, X Su, V Williams, Q Ye, L Zheng and T Zhang are employed (other than primary affiliation; e.g., consulting) by AstraZeneca. L Blockley, E Donald, P Elvin, G Harrod, J Stevens, J Morten, C Cresswell, A Davies, A Gladwin and C Womack are employed by and own shares in AstraZeneca. J-S Lee has received research funding from AstraZeneca. R de Boer has received research funding and honoraria as a consultant from AstraZeneca. J Vasselli is employed by MedImmune. R Herbst has no potential conflicts of interest.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>AP, PE, JM, ED, AG, CW and QJ were involved in the conception and design of the study. XS, ED, VW, GB and CW developed the methodology for the study. All authors obtained data for the study. The analysis and interpretation of the data was performed by AP, JM, GB, LB, CC, AD, AD, NG, SF, HF, GH, JR, JS, VW, QY, TZ, QJ, XS, LZ, ED, CW and PE. All authors contributed to the writing and critical review of the manuscript. All authors read and approved the final manuscript.</p></fn><fn><p><bold>Authors&#x02019; information</bold></p><p>Dr Womack was employed by AstraZeneca at the time of the study.</p></fn></fn-group><ack><p>We dedicate this article to the memory of our colleague Neil Gray, FIBMS.</p><p>The authors would like to acknowledge John Williams for facilitating the delivery of the contracts with external parties to time, quality and cost, Darren Hodgson for clinical data management, transmission, reporting and critical review of data analysis files, and Jennifer Bradford for assistance with analysis and interpretation.</p><p>This study was sponsored by AstraZeneca. Medical writing assistance was provided by Claire Routley from Mudskipper Business Ltd and funded by AstraZeneca.</p><sec id="FPar1"><title>Financial support</title><p>This study was sponsored by AstraZeneca.</p><p>Previously presented at American Society for Clinical Oncology (ASCO) 2013; <italic>J Clin Oncol</italic> 31:(suppl; abst 8045).</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oxnard</surname><given-names>GR</given-names></name><name><surname>Binder</surname><given-names>A</given-names></name><name><surname>Janne</surname><given-names>PA</given-names></name></person-group><article-title>New targetable oncogenes in non-small-cell lung cancer</article-title><source>J Clin Oncol</source><year>2013</year><volume>31</volume><fpage>1097</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1200/JCO.2012.42.9829</pub-id><pub-id pub-id-type="pmid">23401445</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohno</surname><given-names>T</given-names></name><name><surname>Ichikawa</surname><given-names>H</given-names></name><name><surname>Totoki</surname><given-names>Y</given-names></name><name><surname>Yasuda</surname><given-names>K</given-names></name><name><surname>Hiramoto</surname><given-names>M</given-names></name><name><surname>Nammo</surname><given-names>T</given-names></name><etal/></person-group><article-title><italic>KIF5B-RET</italic> fusions in lung adenocarcinoma</article-title><source>Nat Med</source><year>2012</year><volume>18</volume><fpage>375</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1038/nm.2644</pub-id><pub-id pub-id-type="pmid">22327624</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipson</surname><given-names>D</given-names></name><name><surname>Capelletti</surname><given-names>M</given-names></name><name><surname>Yelensky</surname><given-names>R</given-names></name><name><surname>Otto</surname><given-names>G</given-names></name><name><surname>Parker</surname><given-names>A</given-names></name><name><surname>Jarosz</surname><given-names>M</given-names></name><etal/></person-group><article-title>Identification of new <italic>ALK</italic> and <italic>RET</italic> gene fusions from colorectal and lung cancer biopsies</article-title><source>Nat Med</source><year>2012</year><volume>18</volume><fpage>382</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1038/nm.2673</pub-id><pub-id pub-id-type="pmid">22327622</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ju</surname><given-names>YS</given-names></name><name><surname>Lee</surname><given-names>WC</given-names></name><name><surname>Shin</surname><given-names>JY</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Bleazard</surname><given-names>T</given-names></name><name><surname>Won</surname><given-names>JK</given-names></name><etal/></person-group><article-title>A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing</article-title><source>Genome Res</source><year>2012</year><volume>22</volume><fpage>436</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1101/gr.133645.111</pub-id><pub-id pub-id-type="pmid">22194472</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>W</given-names></name><name><surname>Su</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Fan</surname><given-names>L</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Fei</surname><given-names>K</given-names></name><etal/></person-group><article-title><italic>KIF5B-RET</italic> fusions in Chinese patients with non-small cell lung cancer</article-title><source>Cancer</source><year>2013</year><volume>119</volume><fpage>1486</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1002/cncr.27940</pub-id><pub-id pub-id-type="pmid">23378251</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drilon</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Hasanovic</surname><given-names>A</given-names></name><name><surname>Suehara</surname><given-names>Y</given-names></name><name><surname>Lipson</surname><given-names>D</given-names></name><name><surname>Stephens</surname><given-names>P</given-names></name><etal/></person-group><article-title>Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas</article-title><source>Cancer Discov</source><year>2013</year><volume>3</volume><fpage>630</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-13-0035</pub-id><pub-id pub-id-type="pmid">23533264</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Fang</surname><given-names>R</given-names></name><name><surname>Fang</surname><given-names>Z</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>X</given-names></name><etal/></person-group><article-title>Identification of RET gene fusion by exon array analyses in &#x0201c;pan-negative&#x0201d; lung cancer from never smokers</article-title><source>Cell Res</source><year>2012</year><volume>22</volume><fpage>928</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1038/cr.2012.27</pub-id><pub-id pub-id-type="pmid">22349463</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasaki</surname><given-names>H</given-names></name><name><surname>Shimizu</surname><given-names>S</given-names></name><name><surname>Tani</surname><given-names>Y</given-names></name><name><surname>Maekawa</surname><given-names>M</given-names></name><name><surname>Okuda</surname><given-names>K</given-names></name><name><surname>Yokota</surname><given-names>K</given-names></name><etal/></person-group><article-title>RET expression and detection of KIF5B/RET gene rearrangements in Japanese lung cancer</article-title><source>Cancer Med</source><year>2012</year><volume>1</volume><fpage>68</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1002/cam4.13</pub-id><pub-id pub-id-type="pmid">23342255</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suehara</surname><given-names>Y</given-names></name><name><surname>Arcila</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Hasanovic</surname><given-names>A</given-names></name><name><surname>Ang</surname><given-names>D</given-names></name><name><surname>Ito</surname><given-names>T</given-names></name><etal/></person-group><article-title>Identification of <italic>KIF5B-RET</italic> and <italic>GOPC-ROS1</italic> fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions</article-title><source>Clin Cancer Res</source><year>2012</year><volume>18</volume><fpage>6599</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-0838</pub-id><pub-id pub-id-type="pmid">23052255</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeuchi</surname><given-names>K</given-names></name><name><surname>Soda</surname><given-names>M</given-names></name><name><surname>Togashi</surname><given-names>Y</given-names></name><name><surname>Suzuki</surname><given-names>R</given-names></name><name><surname>Sakata</surname><given-names>S</given-names></name><name><surname>Hatano</surname><given-names>S</given-names></name><etal/></person-group><article-title>RET, ROS1 and ALK fusions in lung cancer</article-title><source>Nat Med</source><year>2012</year><volume>18</volume><fpage>378</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1038/nm.2658</pub-id><pub-id pub-id-type="pmid">22327623</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Pan</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Ye</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><etal/></person-group><article-title><italic>RET</italic> fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer</article-title><source>J Clin Oncol</source><year>2012</year><volume>30</volume><fpage>4352</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1200/JCO.2012.44.1477</pub-id><pub-id pub-id-type="pmid">23150706</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokota</surname><given-names>K</given-names></name><name><surname>Sasaki</surname><given-names>H</given-names></name><name><surname>Okuda</surname><given-names>K</given-names></name><name><surname>Shimizu</surname><given-names>S</given-names></name><name><surname>Shitara</surname><given-names>M</given-names></name><name><surname>Hikosaka</surname><given-names>Y</given-names></name><etal/></person-group><article-title><italic>KIF5B/RET</italic> fusion gene in surgically-treated adenocarcinoma of the lung</article-title><source>Oncol Rep</source><year>2012</year><volume>28</volume><fpage>1187</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">22797671</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanzi</surname><given-names>C</given-names></name><name><surname>Borrello</surname><given-names>MG</given-names></name><name><surname>Bongarzone</surname><given-names>I</given-names></name><name><surname>Migliazza</surname><given-names>A</given-names></name><name><surname>Fusco</surname><given-names>A</given-names></name><name><surname>Grieco</surname><given-names>M</given-names></name><etal/></person-group><article-title>Identification of the product of two oncogenic rearranged forms of the RET proto-oncogene in papillary thyroid carcinomas</article-title><source>Oncogene</source><year>1992</year><volume>7</volume><fpage>2189</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">1437145</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carlson</surname><given-names>KM</given-names></name><name><surname>Dou</surname><given-names>S</given-names></name><name><surname>Chi</surname><given-names>D</given-names></name><name><surname>Scavarda</surname><given-names>N</given-names></name><name><surname>Toshima</surname><given-names>K</given-names></name><name><surname>Jackson</surname><given-names>CE</given-names></name><etal/></person-group><article-title>Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B</article-title><source>Proc Natl Acad Sci U S A</source><year>1994</year><volume>91</volume><fpage>1579</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1073/pnas.91.4.1579</pub-id><pub-id pub-id-type="pmid">7906417</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donis-Keller</surname><given-names>H</given-names></name><name><surname>Dou</surname><given-names>S</given-names></name><name><surname>Chi</surname><given-names>D</given-names></name><name><surname>Carlson</surname><given-names>KM</given-names></name><name><surname>Toshima</surname><given-names>K</given-names></name><name><surname>Lairmore</surname><given-names>TC</given-names></name><etal/></person-group><article-title>Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC</article-title><source>Hum Mol Genet</source><year>1993</year><volume>2</volume><fpage>851</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1093/hmg/2.7.851</pub-id><pub-id pub-id-type="pmid">8103403</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulligan</surname><given-names>LM</given-names></name><name><surname>Kwok</surname><given-names>JB</given-names></name><name><surname>Healey</surname><given-names>CS</given-names></name><name><surname>Elsdon</surname><given-names>MJ</given-names></name><name><surname>Eng</surname><given-names>C</given-names></name><name><surname>Gardner</surname><given-names>E</given-names></name><etal/></person-group><article-title>Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A</article-title><source>Nature</source><year>1993</year><volume>363</volume><fpage>458</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1038/363458a0</pub-id><pub-id pub-id-type="pmid">8099202</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elisei</surname><given-names>R</given-names></name><name><surname>Cosci</surname><given-names>B</given-names></name><name><surname>Romei</surname><given-names>C</given-names></name><name><surname>Bottici</surname><given-names>V</given-names></name><name><surname>Renzini</surname><given-names>G</given-names></name><name><surname>Molinaro</surname><given-names>E</given-names></name><etal/></person-group><article-title>Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study</article-title><source>J Clin Endocrinol Metab</source><year>2008</year><volume>93</volume><fpage>682</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1210/jc.2007-1714</pub-id><pub-id pub-id-type="pmid">18073307</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wedge</surname><given-names>SR</given-names></name><name><surname>Ogilvie</surname><given-names>DJ</given-names></name><name><surname>Dukes</surname><given-names>M</given-names></name><name><surname>Kendrew</surname><given-names>J</given-names></name><name><surname>Chester</surname><given-names>R</given-names></name><name><surname>Jackson</surname><given-names>JA</given-names></name><etal/></person-group><article-title>ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration</article-title><source>Cancer Res</source><year>2002</year><volume>62</volume><fpage>4645</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">12183421</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carlomagno</surname><given-names>F</given-names></name><name><surname>Vitagliano</surname><given-names>D</given-names></name><name><surname>Guida</surname><given-names>T</given-names></name><name><surname>Ciardiello</surname><given-names>F</given-names></name><name><surname>Tortora</surname><given-names>G</given-names></name><name><surname>Vecchio</surname><given-names>G</given-names></name><etal/></person-group><article-title>ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases</article-title><source>Cancer Res</source><year>2002</year><volume>62</volume><fpage>7284</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">12499271</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsubara</surname><given-names>D</given-names></name><name><surname>Kanai</surname><given-names>Y</given-names></name><name><surname>Ishikawa</surname><given-names>S</given-names></name><name><surname>Ohara</surname><given-names>S</given-names></name><name><surname>Yoshimoto</surname><given-names>T</given-names></name><name><surname>Sakatani</surname><given-names>T</given-names></name><etal/></person-group><article-title>Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad</article-title><source>J Thorac Oncol</source><year>2012</year><volume>7</volume><fpage>1872</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1097/JTO.0b013e3182721ed1</pub-id><pub-id pub-id-type="pmid">23154560</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herbst</surname><given-names>RS</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Eberhardt</surname><given-names>WE</given-names></name><name><surname>Germonpre</surname><given-names>P</given-names></name><name><surname>Saijo</surname><given-names>N</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><etal/></person-group><article-title>Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial</article-title><source>Lancet Oncol</source><year>2010</year><volume>11</volume><fpage>619</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(10)70132-7</pub-id><pub-id pub-id-type="pmid">20570559</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Boer</surname><given-names>RH</given-names></name><name><surname>Arrieta</surname><given-names>&#x000d3;</given-names></name><name><surname>Yang</surname><given-names>C-H</given-names></name><name><surname>Gottfried</surname><given-names>M</given-names></name><name><surname>Chan</surname><given-names>V</given-names></name><name><surname>Raats</surname><given-names>J</given-names></name><etal/></person-group><article-title>Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind Phase III trial</article-title><source>J Clin Oncol</source><year>2011</year><volume>29</volume><fpage>1067</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1200/JCO.2010.29.5717</pub-id><pub-id pub-id-type="pmid">21282537</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Natale</surname><given-names>RB</given-names></name><name><surname>Thongprasert</surname><given-names>S</given-names></name><name><surname>Greco</surname><given-names>FA</given-names></name><name><surname>Thomas</surname><given-names>M</given-names></name><name><surname>Tsai</surname><given-names>C-M</given-names></name><name><surname>Sunpaweravong</surname><given-names>P</given-names></name><etal/></person-group><article-title>Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer</article-title><source>J Clin Oncol</source><year>2011</year><volume>29</volume><fpage>1059</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1200/JCO.2010.28.5981</pub-id><pub-id pub-id-type="pmid">21282542</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Hirsh</surname><given-names>V</given-names></name><name><surname>Park</surname><given-names>K</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Blajman</surname><given-names>CR</given-names></name><name><surname>Perng</surname><given-names>R-P</given-names></name><etal/></person-group><article-title>Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind Phase III trial (ZEPHYR)</article-title><source>J Clin Oncol</source><year>2012</year><volume>30</volume><fpage>1114</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1200/JCO.2011.36.1709</pub-id><pub-id pub-id-type="pmid">22370318</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">AstraZeneca. Global Policy: Bioethics. 2011. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.astrazeneca.com/Responsibility/Code-policies-standards/Our-global-policies">http://www.astrazeneca.com/Responsibility/Code-policies-standards/Our-global-policies</ext-link>.</mixed-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">MHRA. Good Clinical Practice for Clinical Laboratories. 2009. Available at: <ext-link ext-link-type="uri" xlink:href="http://webarchive.nationalarchives.gov.uk/20141205150130/http://www.mhra.gov.uk/home/groups/is-insp/documents/websiteresources/con051910.pdf">http://webarchive.nationalarchives.gov.uk/20141205150130/http://www.mhra.gov.uk/home/groups/is-insp/documents/websiteresources/con051910.pdf</ext-link>.</mixed-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>L</given-names></name><name><surname>Su</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Yin</surname><given-names>X</given-names></name><name><surname>Tang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group><article-title>FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547</article-title><source>Clin Cancer Res</source><year>2013</year><volume>19</volume><fpage>2572</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-3898</pub-id><pub-id pub-id-type="pmid">23493349</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Go</surname><given-names>H</given-names></name><name><surname>Jung</surname><given-names>YJ</given-names></name><name><surname>Kang</surname><given-names>HW</given-names></name><name><surname>Park</surname><given-names>IK</given-names></name><name><surname>Kang</surname><given-names>CH</given-names></name><name><surname>Lee</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Diagnostic method for the detection of KIF5B-RET transformation in lung adenocarcinoma</article-title><source>Lung Cancer</source><year>2013</year><volume>82</volume><fpage>44</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2013.07.009</pub-id><pub-id pub-id-type="pmid">23932363</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gautschi</surname><given-names>O</given-names></name><name><surname>Zander</surname><given-names>T</given-names></name><name><surname>Keller</surname><given-names>FA</given-names></name><name><surname>Strobel</surname><given-names>K</given-names></name><name><surname>Hirschmann</surname><given-names>A</given-names></name><name><surname>Aebi</surname><given-names>S</given-names></name><etal/></person-group><article-title>A patient with lung adenocarcinoma and RET fusion treated with vandetanib</article-title><source>J Thorac Oncol</source><year>2013</year><volume>8</volume><fpage>e43</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1097/JTO.0b013e31828a4d07</pub-id><pub-id pub-id-type="pmid">23584301</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varella-Garcia</surname><given-names>M</given-names></name><name><surname>Xue</surname><given-names>LG</given-names></name><name><surname>Mahale</surname><given-names>S</given-names></name><name><surname>Berge</surname><given-names>EM</given-names></name><name><surname>Bennati</surname><given-names>C</given-names></name><name><surname>Le</surname><given-names>AT</given-names></name><etal/></person-group><article-title><italic>RET</italic> rearrangements detected by FISH in &#x0201c;pan-negative&#x0201d; lung adenocarcinoma</article-title><source>J Clin Oncol</source><year>2013</year><volume>31</volume><fpage>abstr 8024</fpage></element-citation></ref></ref-list></back></article>